1. Home
  2. CGTX vs BCIC Comparison

CGTX vs BCIC Comparison

Compare CGTX & BCIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGTX
  • BCIC
  • Stock Information
  • Founded
  • CGTX 2007
  • BCIC 2006
  • Country
  • CGTX United States
  • BCIC United States
  • Employees
  • CGTX N/A
  • BCIC N/A
  • Industry
  • CGTX Biotechnology: Pharmaceutical Preparations
  • BCIC Finance: Consumer Services
  • Sector
  • CGTX Health Care
  • BCIC Finance
  • Exchange
  • CGTX Nasdaq
  • BCIC Nasdaq
  • Market Cap
  • CGTX 158.8M
  • BCIC 159.5M
  • IPO Year
  • CGTX 2021
  • BCIC N/A
  • Fundamental
  • Price
  • CGTX $1.66
  • BCIC $12.62
  • Analyst Decision
  • CGTX Strong Buy
  • BCIC
  • Analyst Count
  • CGTX 3
  • BCIC 0
  • Target Price
  • CGTX $2.83
  • BCIC N/A
  • AVG Volume (30 Days)
  • CGTX 1.3M
  • BCIC 49.9K
  • Earning Date
  • CGTX 11-06-2025
  • BCIC 11-06-2025
  • Dividend Yield
  • CGTX N/A
  • BCIC 15.06%
  • EPS Growth
  • CGTX N/A
  • BCIC 329.50
  • EPS
  • CGTX N/A
  • BCIC 1.64
  • Revenue
  • CGTX N/A
  • BCIC $58,080,000.00
  • Revenue This Year
  • CGTX N/A
  • BCIC N/A
  • Revenue Next Year
  • CGTX N/A
  • BCIC $14.84
  • P/E Ratio
  • CGTX N/A
  • BCIC $7.71
  • Revenue Growth
  • CGTX N/A
  • BCIC N/A
  • 52 Week Low
  • CGTX $0.22
  • BCIC $11.12
  • 52 Week High
  • CGTX $3.83
  • BCIC $18.80
  • Technical
  • Relative Strength Index (RSI)
  • CGTX 48.96
  • BCIC N/A
  • Support Level
  • CGTX $1.54
  • BCIC N/A
  • Resistance Level
  • CGTX $1.77
  • BCIC N/A
  • Average True Range (ATR)
  • CGTX 0.13
  • BCIC 0.00
  • MACD
  • CGTX -0.01
  • BCIC 0.00
  • Stochastic Oscillator
  • CGTX 31.49
  • BCIC 0.00

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

About BCIC BCP Investment Corporation Common Stock

BCP Investment Corp is a closed-end, externally managed, non-diversified management investment company. The company invests in performing, well- established middle market businesses that operate across a wide range of industries. It employs fundamental credit analysis, targeting investments in businesses with relatively low levels of cyclicality and operating risk.

Share on Social Networks: